Tanovea® (first named GS-9219, then VDC-1101, generic name: rabacfosadine) is a pro-prodrug or "double" prodrug of PMEG [9-(2-phosphonylmethoxyethyl)guanine], which has been conditionally approved by the US FDA (Food and Drug Administration) for the treatment of lymphoma in dogs. Tanovea has been demonstrated to be effective against non-Hodgkin's lymphoma (NHL) in dogs, as well as canine cutaneous T-cell lymphoma, spontaneous canine multiple myeloma, naïve canine multicentric lymphoma and relapsed canine B-cell lymphoma. As a double prodrug of PMEG, GS-9219 is first converted intracellularly by hydrolysis to cPr-PMEDAP, then deaminated to PMEG, which is then phosphorylated twice to its active metabolite PMEGpp, acting at the level of the cellular DNA polymerases.
Guido Rychen, Gabriele Aquilina, Giovanna Azimonti, Vasileios Bampidis, Maria de Lourdes Bastos, Georges Bories, Andrew Chesson, Pier Sandro Cocconcelli, Gerhard Flachowsky, Jürgen Gropp, Boris Kolar, Maryline Kouba, Secundino López Puente, Marta López‐Alonso, Alberto Mantovani, Baltasar Mayo, Fernando Ramos, Roberto Edoardo Villa, Robert John Wallace, Pieter Wester, Rosella Brozzi, Maria Saarela
Benoît Hédan, Mélanie Rault, Jérôme Abadie, Ronan Ulvé, Nadine Botherel, Patrick Devauchelle, Christiane Copie‐Bergman, Édouard Cadieu, Marie Parrens, Julia Alten, Emmanuelle L. Zalcman, Gunnar Cario, Gandhi Damaj, Karima Mokhtari, François Le Loarer, Aurore Coulomb L’Herminé, Thomas Derrien, Christophe Hitte, Laura Bachelot, Matthew Breen, David Gilot, Jean Yves Blay, Jean Donadieu, Catherine André
Discussion(0)
No comments yet. Be the first to comment.